ClinicalTrials.gg
Not yet recruitingNCT07947121Updated Nov 18, 2026

A Study of Risvutatug Rezetecan in Combination With Atezolizumab in Participants With Extensive Stage Small Cell Lung Cancer (EMBOLD-SCLC-303)

A Phase 3 interventional study of Ris-Rez and Atezolizumab in Lung Neoplasm, sponsored by GlaxoSmithKline. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionSmall Cell Lung CarcinomaRegistry: Lung NeoplasmsReclassifiedWhy we changed it
Registry
Lung Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Small Cell Lung Carcinoma
Why
  1. The study's title name Small Cell Lung Carcinoma, a narrower term within Lung Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
700
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 18 studies in Small Cell Lung Carcinoma by GlaxoSmithKline — 2 open to participants now, 2 under way, 2 of them phase 3. Small Cell Lung Carcinoma · GlaxoSmithKline.

Planned enrollment
2nd of 16
700 · median 84
Started
2026
the only one that year
Phase 3
5 of 18
2 open now
Registered
18th of 18
by date

Among the 18 studies in Small Cell Lung Carcinoma by GlaxoSmithKline, this one is the 2nd largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2026, is one of 5 in phase 3, and was the 18th registered.

Small Cell Lung Carcinoma

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

2 of the 18 studies in Small Cell Lung Carcinoma by GlaxoSmithKline are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Small Cell Lung Carcinoma by GlaxoSmithKline, or all of them as a file.
02

Study summary

Extensive-stage small cell lung cancer (ES-SCLC) is an aggressive type of lung cancer. Current treatment options are limited, and response to treatment may not last long. Outcomes are especially poor when the cancer has spread to the brain. This study tests whether a new treatment: risvutatug rezetecan (Ris-Rez) with atezolizumab works better than standard of care treatment. Ris-Rez is designed to deliver cancer-killing medicine directly to cancer cells. Atezolizumab helps the immune system attack cancer cells. Researchers will see if this combination helps people live longer and keeps the cancer from getting worse.

03

Conditions studied

  • Lung Neoplasm

Browse trials for

Keywords

  • Small Cell Lung Cancer
  • Risvutatug Rezetecan
  • Ris-Rez
  • Atezolizumab
  • EMBOLD-SCLC-303
04

In context

Small Cell Lung Carcinoma Reclassified

1,302 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

This study's planned enrollment of 700 is above the median of 56 across 1,078 interventional studies indexed under Small Cell Lung Carcinoma.

Browse Small Cell Lung Carcinoma studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,652 studies on the registry; 118 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 241 (90%) have results posted.

Compared within Small Cell Lung Carcinoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is at least 18 years of age or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the form (ICF).
  • Has or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC) at initial diagnosis and at trial entry and has received no prior systemic therapies for SCLC, with 1 exception where participants who have received one cycle of etoposide and carboplatin with or without atezolizumab are eligible
  • Is capable of giving signed informed consent including compliance with the requirements and restrictions listed in the ICF and protocol.
  • Has an (ECOG) performance status of 0 or 1.
  • Has adequate organ function.

Exclusion criteria

Exclusion Criteria:

  • Has symptomatic central nervous system (CNS) , with hemorrhagic features, or .
  • Has known allergy or to study intervention components or .
  • Has any evidence of current interstitial lung disease or non-infectious pneumonitis or a prior history of interstitial lung disease (ILD) or non-infectious pneumonitis requiring high dose or suspected ILD/non-infectious pneumonitis that cannot be ruled out by imaging.
  • Has moderate to severe pulmonary disease or current pulmonary compromise that, in the investigator's judgment, could jeopardize safety or study conduct.
  • Has clinically significant bleeding symptoms, bleeding tumors, or significant bleeding tendency within 1 month prior to first dose.
  • Known active infectious diseases requiring systemic treatment or known (HIV).
  • Has received any prior systemic anticancer treatment for the disease under study.
  • Has received any prior therapy with a Topoisomerase-1 (TOP1i), including antibody-drug conjugates that are effectively loaded as TOP1i, or treatment targeting B7-H3.
  • Has severe, uncontrolled, or active cardiovascular disorders.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
700 participants (estimated)

Study arms

  • Experimental
    Ris-Rez + atezolizumab

    Biological: Ris-Rez · Biological: Atezolizumab

  • Active comparator
    Etoposide, carboplatin, atezolizumab ± lurbinectedin

    Participants will receive etoposide, carboplatin, atezolizumab with or without lurbinectedin.

    Biological: Atezolizumab · Drug: Etoposide · Drug: Carboplatin · Drug: Lurbinectedin

Interventions

  • BiologicalRis-Rez

    Ris-Rez will be administered.

  • BiologicalAtezolizumab

    Atezolizumab will be administered.

  • DrugEtoposide

    Etoposide will be administered.

  • DrugCarboplatin

    Carboplatin will be administered.

  • DrugLurbinectedin

    Lurbinectedin will be administered.

07

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    OS is defined as the time from the date of randomization to the date of death due to any cause.

    Time frame: Up to 50 months

  2. Progression-free survival (PFS) by Blinded independent central review (BICR) assessment

    PFS is defined as the time from the date of randomization to the date of first documented objective tumor progression per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 by BICR assessment or death from any cause, whichever occurs first.

    Time frame: Up to 50 months

Secondary outcomes

  1. Time to confirmed deterioration of disease-related symptoms and physical functioning

    Time from the date of randomization to the first confirmed clinically meaningful deterioration in disease related symptoms and physical functioning using validated questionnaires will be measured.

    Time frame: Up to 63 months

  2. Brain PFS

    Brain PFS is defined as the time from the date of randomization to the date of first documented brain disease progression (PD) per modified Response assessment in neuro-oncology brain metastases (RANO-BM) by BICR assessment or death from any cause, whichever occurs first in participants with a presence of brain metastases at baseline.

    Time frame: Up to 63 months

  3. PFS by Investigator Assessment

    PFS is defined as the time from the date of randomization to the date of first documented PD per RECIST 1.1 by investigator assessment or death from any cause, whichever occurs first.

    Time frame: Up to 63 months

  4. Objective response rate (ORR)

    ORR is defined as the percentage of participants with best overall confirmed response of either complete response (CR) or partial response (PR) per RECIST 1.1 by RECIST-BICR assessment.

    Time frame: Up to 63 months

  5. Duration of response (DOR)

    DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first.

    Time frame: Up to 63 months

  6. ORR for participants not receiving bridging cycle

    ORR is defined as the percentage of participants with best overall confirmed response of either CR or PR per RECIST 1.1 by RECIST-BICR assessment

    Time frame: Up to 63 months

  7. DOR for participants not receiving bridging cycle

    DOR is defined as the time from the date of first documented objective response (CR or PR) that is subsequently confirmed per RECIST 1.1 by RECIST-BICR assessment to the date of first documented PD per RECIST 1.1 by BICR assessment or death due to any cause, whichever occurs first.

    Time frame: Up to 63 months

  8. Participant reported experience on study treatment

    Number of participants who reported their experience with study treatment using validated questionnaires will be measured.

    Time frame: Up to 63 months

  9. Time to worsening of participants overall quality of life

    Time from the date of randomization to the first confirmed clinically meaningful deterioration in overall quality of life using validated questionnaires will be measured.

    Time frame: Up to 63 months

  10. Number of participants with adverse events (AEs), serious adverse events (SAEs), adverse events of special interest (AESIs) by severity

    Time frame: Up to 63 months

  11. Number of participants with AEs leading to dose modifications or study intervention discontinuation

    Time frame: Up to 63 months

  12. Number of participants with changes in hematology parameters

    Time frame: Up to 63 months

  13. Observed pharmacokinetic concentration of Ris-Rez

    Time frame: Up to 63 months

  14. Number of participants with Antidrug antibody (ADA) and Neutralizing Antibody (NAb) against Ris-Rez

    Time frame: Up to 63 months

  15. Titres of ADA against Ris-Rez

    Time frame: Up to 63 months

08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/gsk-patient-level-data-sharing-july2025.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2031, 49 months later.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's planned 49 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Dec 25, 2026
Primary completionEst.
Feb 24, 2031
CompletionEst.
Mar 24, 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07947121
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Dec 25, 2026 (estimated)
Primary completion
Feb 24, 2031 (estimated)
Completion
Mar 24, 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466
GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion